Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author holds a long position in SDGR.

← Back to Free Index

SDGR

Analysis as of: 2026-04-28

Schrödinger, Inc.

Schrödinger sells computational molecular design software to life sciences and industrial customers and also uses the platform in partnered and proprietary drug discovery programs.

ai biotech enterprise healthcare software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Workflow Control Could Unlock a Cleaner Multiple

The upside case is a cleaner software-plus-royalty story: deeper workflow control, steadier hosted revenue, and externalized pipeline funding. The constraint is proof that customers view the system as essential infrastructure rather than as a high-end modeling tool.

Analysis

Thesis

Schrödinger can compound into a larger, cleaner discovery-software franchise if LiveDesign becomes the governed workflow layer for AI-native R&D, hosted contracts make ACV more durable, and therapeutics upside is externalized into milestones and royalties instead of reviving a heavy internal biotech burn.

Last Economy Alignment

Cheaper compute and better models increase the value of its simulation-led discovery workflows, and workflow embedding can shift value capture toward trust, coordination, and governed execution. The score stops short of very high because Schrödinger does not own the underlying compute stack and still faces internal-build and open-tool substitution risk.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

3.3x (from 5 most recent analyses)

Reasoning

This is a quality-upgrade case, not a moonshot clinical bet. If hosted contracts make revenue steadier, large accounts expand from tools into program workflows, and platform-derived assets are monetized through partners instead of balance-sheet-heavy development, the business can look more like vertical software with option-rich royalties and less like a mixed biotech story.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The biggest risk is that Schrödinger remains a respected modeling tool rather than the operating layer for discovery programs. If hosted contracts only change accounting, large pharma builds more workflow in-house, or internal assets fail to monetize through partners, revenue quality improves too slowly for a durable rerating.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

On April 21, 2026, the company set May 5, 2026 for first-quarter results, making ACV trajectory, hosted-transition effects, and cash discipline the immediate repricing surface.
On April 27, 2026, the proxy proposed adding 3.0 million shares to the equity plan, which modestly raises long-run dilution sensitivity.
No new clinical or commercial disclosure in the last week changed the core thesis; the debate is still centered on software proof and capital discipline.

Forecast update

Upside framing is slightly tighter because the current setup supports a cleaner but still moderate rerating rather than a dramatic one.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.55

They control a real workflow layer inside drug discovery teams, and that can get stickier as AI makes design work faster and more collaborative. The risk is that pharma keeps the important data and uses cheaper internal or third-party agents, leaving Schrödinger as a helpful tool instead of the control point.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$20.50

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research